Today, the Harvard Innovation Labs announced the 11 ventures that are based in the Pagliuca Harvard Life Lab to start 2023.
Located on Harvard’s Allston campus, the Pagliuca Harvard Life Lab’s 15,000-square foot facility features a fully-equipped and permitted wet laboratory and collaborative co-working space. As part of the Harvard Innovation Labs ecosystem, ventures have access to robust programming and resources — from business-building and industry-specific programming to expert advisors and mentors.
Since opening its doors in the fall of 2016, more than 50 ventures have worked out of the Pagliuca Harvard Life Lab. Collectively, these ventures have raised more than $850 million in venture capital funding and created hundreds of jobs.
“One of the most powerful aspects of the Pagliuca Harvard Life Lab is the camaraderie that develops among the people that are sharing our state-of-the-art co-working and lab space,” commented Matt Segneri, Bruce and Bridgitt Evans Executive Director of the Harvard Innovation Labs. “The Life Lab has been home to high-potential ventures focused on an incredible range of innovations, from in vivo biologics design to infectious disease diagnostics. Founders and teams working out of the Life Lab have an opportunity to learn from one another and tap into a breadth of experts, equipment, and resources as they move their ventures forward.”
Current Life Lab founders represent four different Harvard schools, and 45% of the ventures have a woman founder or co-founder. The 11 ventures working out of the Pagliuca Harvard Life Lab include:
Aperture Biosystems: Commercializing highly multiplexed single cell analysis technology for serial tumor immunoprofiling.
BioDevek: Improving clinical outcomes following internal surgeries using degradable biomaterials.
Ilios Therapeutics: Leveraging proprietary therapeutics molecules with strong antioxidant and anti-inflammatory properties to prevent and counter neurodegeneration.
InGel Therapeutics: Leveraging stem cell and tissue engineering to rescue and restore vision for blind patients.
Kern Systems: Leveraging enzymes and cutting-edge software to store digital data in DNA at scale.
Kestrel Therapeutics: Discovering and developing new molecules to treat intractable cancers.
Limax Biosciences: Developing a degradable adhesive hydrogel to augment vascular reconstruction and serve as a hemostatic agent in advanced bleeding scenarios.
Promakhos Therapeutics: Focusing on local and controlled modulation of the immune system to restore homeostasis.
Stratagen Bio: Transforming treatment planning, beginning with long-term monitoring of tissue oxygen.
Stylus Medicines: Pioneering a new class of therapies powered by a suite of technologies, including novel enzymes, that enable large DNA insertions.
Terascale: Creating a synthetic chemistry approach to create low-cost, efficient solar panels.